News & Updates
Filter by Specialty:
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
Treatment with oral ritlecitinib improves outcomes in patients with active nonsegmental vitiligo, without any serious adverse events over 48 weeks, results of a study have shown.
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
27 Jan 2023
Online on par with in-person care for improving outcomes in psoriasis
An online health model appears to be as effective as in-person care for decreasing functional impairment and depressive symptoms in patients with psoriasis, according to a study.
Online on par with in-person care for improving outcomes in psoriasis
26 Jan 2023
Multiple moles, genetic predisposition up risk of second primary melanomas
Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.
Multiple moles, genetic predisposition up risk of second primary melanomas
22 Jan 2023
Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD
Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.
Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD
16 Jan 2023
Tralokinumab improves skin microbial dysbiosis in atopic dermatitis
In patients with atopic dermatitis (AD), treatment with the IL-13 cytokine-targeting tralokinumab appears to directly or indirectly improves skin microbial dysbiosis, reports a new trial.
Tralokinumab improves skin microbial dysbiosis in atopic dermatitis
10 Dec 2022
Exposure to air pollution ups risk of atopic dermatitis
Long-term exposure to air pollutants, including gases and particulate matter, may increase the risk of developing atopic dermatitis (AD), according to a recent study.